AMSTERDAM, the Netherlands – July 16, 2015 – NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced that Jason M. Hannon has been appointed Executive Vice President, International where he will responsible for the Company’s business and commercial operations outside of the United States, including leading the Company’s international expansion opportunities.
The appointment of Mr. Hannon marks an important strategic step in support of NuVasive’s commitment to accelerate its global expansion and market share-taking efforts in key international growth markets. Mr. Hannon will be relocating to NuVasive’s International headquarters in Amsterdam, the Netherlands where he will drive the Company’s international expansion strategy and continue to build out the infrastructure needed to more rapidly expand the Company’s global footprint. The Company currently provides its minimally disruptive, procedurally-integrated spine surgery solutions in more than 30 countries, including Japan, Australia, the United Kingdom, Italy, Germany, Spain, Argentina, Brazil and throughout Southeast Asia.
“We are pleased to have Jason leading our highly capable international team as we look to capitalize on the strong foundation we have built across our Latin America, European and Asia-Pacific markets,” said Gregory T. Lucier, NuVasive’s Chairman and Chief Executive Officer. “As a 10 year veteran of NuVasive, Jason is uniquely positioned to lead our international expansion efforts. He brings vast knowledge of not only our Company, but of the global markets and competitive landscape to his new role, as well as business acumen and extensive corporate development experience. With Jason now leading our efforts internationally, we are well positioned to deliver on NuVasive’s next phase of growth and success as the innovation pioneer in spine on a truly global basis.”
Jason M. Hannon, NuVasive’s Executive Vice President, International, said, “My immediate focus will be centered on globalizing our business growth, including accelerating investments for rapid growth in specific and targeted ways, as well as aggressively pursuing inorganic growth options to supplement NuVasive’s already strong organic expansion. Equally as important will be to ensure NuVasive shareowners around the world have a truly global mindset with a talent base that is strategically aligned. I look forward to spending time in each of our markets, helping to understand the barriers to our growth and prioritizing our most important investments.”
Mr. Hannon brings to his new role extensive experience in key areas of NuVasive’s business, including corporate development, mergers and acquisitions, regulatory and legal expertise. Throughout his tenure at NuVasive, he has been involved in developing and driving the Company’s strategic direction and has played a key leadership role in support of NuVasive’s business growth.
Mr. Hannon will continue to serve as NuVasive’s General Counsel until a successor is identified, for which an active search is underway.
NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally-integrated solutions for the spine. NuVasive has emerged from a small startup to become the #3 player in the $9 billion global spine market and remains focused on market share-taking strategies as the Company continues on its path to become the industry’s leading spine company. NuVasive offers a comprehensive spine portfolio of more than 90 unique products developed to improve spine surgery and patient outcomes. The Company’s principal procedural solution is its Maximum Access Surgery, or MAS®, platform for lateral spine fusion. MAS was designed to provide safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA™ platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
# # #